Shanghai, China, October 31, 2024 — Shanghai CureGene Pharmaceutical Co., Ltd. (referred to as "CureGene Pharmaceutical") announces the completion of a Series B+ funding round. This round was spearheaded by GuoXin Innovation Equity, with other major investors including Aeonmed Group, Infinite Capital, and existing investor Honghai Capital also continued to increase its investment. Qidian Capital served as the financial advisor for this funding round and will continue to provide financing services to the company in the future.

The capital raised in this round will be used to accelerate the clinical development of CG-0255, a core product in the cardiovascular field. Previously, CureGene Pharmaceutical has gained long-term support from many well-known industry institutions, including Tailong Investment, Hankan Capital, and Yonghua Investment. Since founded in Zhangjiang, Shanghai, in 2018, CureGene Pharmaceutical has built a globally leading targeted prodrug platform and nucleic acid drug technologies, focusing on the research and development of small molecule and nucleic acid drugs. Its pipelines include multiple innovative drugs with independent global intellectual property rights and huge market potential.
A new generation of antiplatelet drugs CG-0255, an independently developed product by CureGene Pharmaceutical, is an innovative P2Y12 receptor antagonist with a newly designed metabolic pathway, showing Best-in-Class potential according to clinical data. CG-0255 has completed Phase I clinical trials in both intravenous injection and oral tablet formulations in the U.S., and related results were presented at the 2023 American Heart Association (AHA) annual meeting and 2024 European Society of Cardiology (ESC) annual meetings. The company is actively advancing the registration clinical phase of this product in the U.S. and has submitted a clinical development application in China, where the related clinical work will be followed rapidly.
In addition to the cardiovascular field, CureGene Pharmaceutical has made significant achievements in the antiviral field, with breakthroughs in broad-spectrum respiratory antiviral drugs and functional cure for chronic hepatitis B. These advancements have demonstrated vast clinical application potential.
Dr. He Gongxin, CureGene’s Founder and CEO, has over 30 years of experience in innovative drug development and commercialization. He has participated in and led the development of several international Best-in-Class drugs and he is the main inventor and project leader of multiple blockbuster products currently on the global market. The company's core scientists and operational management team are from world-renowned multinational pharmaceutical companies. They have extensive experience in clinical operations, commercialization and innovative drug R&D including cardiovascular, metabolism, respiratory and antiviral fields.

Dr. He Gongxin, founder of CureGene Pharmaceutical, expressed his profound gratitude: "We are grateful for the high recognition from our investors regarding CureGene's pipelines. The fund raised will accelerate the clinical development of our core products in both China and the U.S. It will also support the global layout of our pipelines. CureGene Pharmaceutical has always been committed to the independent R&D of innovative drugs to address substantial clinical needs. We look forward to collaborating closely with our investors and partners to drive the development and commercialization of our products, benefiting patients and enriching society."
GuoXin Innovation Equity expressed: "We are optimistic about the rich experience and resource accumulated by the company's senior management team in the field of innovative drug development. The core product has already obtained excellent clinical data, which is expected to solve the problems existing in existing therapeutic drugs and has a significant market potential. Moreover, the company has laid out innovative pipelines with substantial clinical value. We hope that this round funding will help the company accelerate its development, advance the clinical and commercialization processes of its products, and provide more treatment options for patients."
Beijing Aeonmed Investment stated: "‘Guard life Sincerely’ is Aeonmed's brand mission, which aligns perfectly with CureGene Pharmaceutical. Aeonmed believes that CureGene's team, through deeply developing the core underlying technology, can carry out new metabolic pathways and make major breakthrough and innovation in drugs such as antiplatelet and anti-respiratory syncytial virus (RSV). CureGene team has created differentiated competitive advantages to make their products stand out. Aeonmed highly recognizes CureGene's comprehensive capabilities in terms of industrialization and medical and industrial integration. Aeonmed is confident that CureGene’s team has the potential to become the leader in this field. Aeonmed looks forward to synergizing with CureGene in areas such as respiratory and geriatric rehabilitation, and is committed to help the company develop rapidly and steadily, bringing new vitality to China's healthcare industry, enhancing national confidence, and providing more opportunities for human health."
Infinite Capital stated: "CureGene Pharmaceutical has assembled a founding team led by Dr. He Gongxin, a former Gilead senior expert. The company has achieved breakthrough achievement in cardiovascular and antiviral fields, with rich drug development experience and mature enterprise management skills. The innovative drug pipelines developed by the company is highly robust and globally competitive. Among them, the next-generation antiplatelet drug CG-0255, with its innovative metabolic pathway, effectively overcomes clopidogrel resistance at lower dose, offers rapid onset with injection, and sequential oral administration, presenting an expansive market outlook. We look forward to CureGene accelerating its clinical development, advancing its international strategy, and continuing to create brilliance on the path of innovative drugs, bringing more benefits to patients."